State-of-the-art Medicines to Abort ResisTance joint laboratory - SMARt-Lab Project
- Team Leader: Nicolas Willand – Professor
- Dr Marion Flipo – Assistant Professor
- Dr Baptiste Villemagne – Assistant Professor
- Dr Mathieu Maingot – Postdoc
- Kevin Antraygues – PhD student
- Dr Ruben Hartkoorn, CIIL, Institut Pasteur Lille
- Dr Alain Baulard, CIIL, Institut Pasteur Lille
- Dr Sushovan Dam, CIIL, Institut Pasteur Lille – Postdoc
- Dr Marc Gitzinger, CEO
- Dr Sergio, Lociuro, SCO
- Dr Olivier Defert
- Dr Vincent Trebosc
BioVersys and partners, the Institut Pasteur de Lille and the University of Lille, from Région Hauts-de-France, have engaged a long-term collaboration agreement creating a unique cross-border cluster of research excellence focused on unmet medical needs in antimicrobial resistance.
BioVersys continues to strengthen ties with two institutes of scientific excellence, the Institut Pasteur de Lille and the University of Lille, with whom we already enjoy a long-standing and fruitful collaboration.
The public-private joint laboratory called “State-of-the-art Medicines to Abort ResisTance joint research laboratory” “SMART-Lab”, funded by FEDER and I-SITE ULNE, builds on the strengths of the collaboration on tuberculosis, to develop new drug discovery programs to address the unmet medical need related to hospital and community acquired infections from high priority Gram-negative and Gram-positive bacteria. SMART-Lab encompasses three research groups, namely those of Prof. Nicolas Willand (INSERM U1177, Drugs and Molecules for Living Systems), Dr. Alain Baulard and Dr. Ruben Hartkoorn (Center of Infection and Immunity of Lille, INSERM U1019 - CNRS UMR8204) at the academic institutions, and BioVersys SAS, a subsidiary of the Swiss biotech BioVersys AG. This creates a unique cross-border AMR Cluster in Antimicrobial Research Excellence (AMR-CARE).